Karyopharm Reports Fourth Quarter and Full Year 2022 Financi

-- Total Revenue of $157.1 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $120.4 Million for Full Year 2022, Meeting Company's Guidance -- --...

Related Keywords

China , Boston , Massachusetts , United States , Tsadal , Kyongsang Bukto , South Korea , United Kingdom , Israel , American , Richard Paulson , Selective Inhibitor Of Nuclear Export , American Society Of Clinical Oncology , Linkedin , European Hematology Association , Nasdaq , American Society Of Hematology , Company Provides Full Year , Karyopharm Selective Inhibitor Of Nuclear Export , Menarini Group , Information Department , Karyopharm Therapeutics Inc , Foundation Medicine Inc , Drug Administration , European Commission , Exchange Commission , Prnewswire Karyopharm Therapeutics Inc , Meeting Company Guidance , Net Product Revenue , Full Year , Meeting Company , Interim Data , Evaluating Eltanexor , Refractory Myelodysplastic Neoplasms Expected , Provides Full Year , Revenue Guidance , Product Revenue Guidance , Cash Runway , Call Scheduled , Chief Executive Officer , Foundation Medicine , American Society , Clinical Oncology , Near Term Catalysts , Operational Objectives , Fourth Quarter , Karyopharm Therapeutics , Selective Inhibitor , Nuclear Export , Medical Information , Fetal Toxicity , Private Securities Litigation Reform Act , Quarterly Report ,